News archives

Home > News archives

Closing of the Series C funding to advance pipeline of novel GPCR antibodies

Aug 24,2021 -- Updated 16:32 +0900 (GMT)

NBHL has closed the Series C funding to advance pipeline of novel GPCR antibodies.

Click here for detail.

Announcement of Agreements with ReCentrics Biotechnology Co. Ltd. and NBHL for Global Collaboration to Development and Commercialize GPCR Antibody Therapies

Aug 24,2021 -- Updated 16:31 +0900 (GMT)

NBHL has singed the Agreements with ReCentrics Biotechnology Co. Ltd. and NBHL for Global Collaboration to Development and Commercialize GPCR Antibody Therapies.

Click here for details.

NBHL will participate in BIO-Europe 2020 – Digital.

Oct 23,2020 -- Updated 18:04 +0900 (GMT)

NBHL will participate in BIO-Europe 2020 – Digital to be held from October 26th to 29th, 2020. We are looking forward to meeting you in virtual partnering meetings to discuss future opportunities on our antibody technology and development pipeline. 

For more information on this event, please visit https://ebdgroup.knect365.com/bioeurope/

 

NBHL will be present at BioJapan 2020 in Yokohama, Japan

Oct 14,2020 -- Updated 10:43 +0900 (GMT)

NBHL will have a panel exhibition at C-13 (in Hokkaido & Sapporo Bio Consortium booth) in “BioJapan 2020” to be held in Pacifico Yokohama, Japan, from October 14th to 16th, 2020. We are looking forward to meeting you via online one-on-one partnering.

For more information on this event, please visit https://www.ics-expo.jp/biojapan/en/

NBHL will participate in BioPharm America 2020 – Digital

Sep 18,2020 -- Updated 19:24 +0900 (GMT)

NBHL will participate in BioPharm America 2020 – Digital to be held from September 21st to 24th, 2020. We are looking forward to meeting you in virtual partnering meetings to discuss future opportunities.

For more information on this event, please visit https://informaconnect.com/biopharm-america/

NBHL will attend Discovery on Target 2020 – Virtual.

Sep 18,2020 -- Updated 10:48 +0900 (GMT)

NBHL will participate in “Discovery on Target 2020 – Virtual” to be held from September 16th to 18th, 2020. Kiyoshi Takayama (President, NBHL) will make a poster presentation on the single cell-based technology for screening and profiling of the anti-GPCR antibodies.

NB Health Laboratory Co. Ltd.

Poster #10. “Discovery of the Therapeutic mAbs Targeting GPCRs with a Unique Single Cell Analysis Technique and mAb Profiling System”

For more information on this event, please visit https://www.discoveryontarget.com/

NBHL will participate in ChinaBio Partnering Forum 2020 – Digital

Aug 17,2020 -- Updated 16:33 +0900 (GMT)

NBHL will participate in ChinaBio Partnering Forum 2020 – Digital to be held from August 25th to 27th, 2020. We are looking forward to meeting you in virtual partnering meetings to discuss future opportunities.

For more information on this event, please visit https://informaconnect.com/chinabio-partnering-forum-virtual/

No opposition filed against NBHL’s European patent for anti-CCR7 antibodies

Apr 22,2020 -- Updated 14:33 +0900 (GMT)

We are informed by European Patent Office that on expiry of the opposition period no notice of opposition has been filed against the NBHL’s European patent for anti-CCR7 antibodies granted in 2019. 

Title of the invention: Anti-human CCR7 antibodies, hybridoma, medical composition, and antibody-immobilized carrier

Patent number: EP 2 623 592

Application number: 11829086.5

Proprietor: NB Health Laboratory Co. Ltd.

 CCR7 is a GPCR involved in the pathogenesis of fibrosis and cancer. We will continue to proceed with the development of therapeutic anti-CCR7 antibodies.

NBHL announces poster presentation at Antibody Engineering & Therapeutics Asia 2020 in Kyoto, Japan

Feb 24,2020 -- Updated 09:00 +0900 (GMT)

Kiyoshi Takayama (President, NBHL) will have a poster presentation at Antibody Engineering & Therapeutics Asia 2020 to be held in The Westin Miyako Kyoto, Japan, from February 24th to 26th, 2020. Our presentation will focus on the new MoGRAA® discovery engine powered by the innovative high-throughput single-cell technology RiGRASSTM for discovering functional anti-GPCR antibodies. Please stop by our poster, and we look forward to meeting you to discuss future collaboration opportunities.

 

[URL]

https://informaconnect.com/antibody-engineering-therapeutics-asia/

 

NBHL will attend BIO CEO & Investor Conference 2020 in New York, USA

Feb 6,2020 -- Updated 15:16 +0900 (GMT)

NBHL will be at the BIO CEO & Investor Conference 2020 to be held in New York from February 10th to 11th, 2020. NBHL’s Business Development team will attend this exciting event. We are looking forward to meeting you in New York to discuss future opportunities.

 

For more information on this event, please visit https://www.bio.org/events/bio-ceo-investor-conference

次へ »